Theriva Biologics, Inc. (TOVX)
| Market Cap | 5.51M -29.4% |
| Revenue (ttm) | 300,000 |
| Net Income | -10.24M |
| EPS | -0.25 |
| Shares Out | 45.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,357,315 |
| Open | 0.1321 |
| Previous Close | 0.1280 |
| Day's Range | 0.1256 - 0.1330 |
| 52-Week Range | 0.1200 - 0.4920 |
| Beta | 1.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About TOVX
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral c... [Read more]
Financial Performance
Financial StatementsNews
Theriva Biologics announces reverse stock split
Theriva Biologics (TOVX) announced a reverse stock split of its authorized and issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share ofā¦
Theriva⢠Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Theriva⢠Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related dise...
Theriva⢠Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
ā VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 ā
Theriva Biologics Quarterly report: Q3 2026
Theriva Biologics has published its Q3 2026 quarterly earnings report on November 12, 2026.
Theriva Biologics Earnings release: Q3 2026
Theriva Biologics released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Theriva⢠Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
ā Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales ā ā Biossi...
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on October 20, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on October 9, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics announces results from VIRAGE Phase 2b trial of VCN-01
Theriva Biologics (TOVX) announced that detailed analysis of results from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer patients were published in Nature Medicine. The a...
Theriva⢠Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
-Ā Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancerĀ - - Data ar...
Theriva⢠Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
ā First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metas...
Theriva Biologics Earnings release: Q2 2026
Theriva Biologics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Theriva Biologics Quarterly report: Q2 2026
Theriva Biologics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Theriva⢠Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
-Ā VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) -
Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain
Theriva Biologics (TOVX) announced that the Spanish Agency of Medicines and Medical Devices, or AEMPS, has authorized the company to initiate the VIRAGE2 clinical trial, entitled āA Phase IIa, single-...
Theriva⢠Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
-Ā VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial - - Study builds on positive clinical data from the recent VIR...
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Theriva⢠Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
ā Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor du...
Theriva Biologics Slides: Corporate presentation
Theriva Biologics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Theriva⢠Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
ā Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) ā
Theriva Biologics Earnings release: Q1 2026
Theriva Biologics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Theriva Biologics Quarterly report: Q1 2026
Theriva Biologics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.